©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
miRNA and platelet genetic machinery
Pedro C Redondo, Department of Physiology, Institute of Molecular Pathology Biomarkers, University of Extremadura, Caceres 10003, Spain
Author contributions: Redondo PC has written the manuscript.
Conflict-of-interest statement: Redondo PC declares no conflict of interest related to this publication.
Corresponding author to: Pedro C Redondo, PhD, Academic Research, Professor, Department of Physiology, Institute of Molecular Pathology Biomarkers, University of Extremadura, Plaza de Caldereros, s/n., Caceres 10003, Spain. pcr@unex.es
Telephone: +34-927-257106 Fax: +34-927-257110
Received: June 29, 2018
Peer-review started: July 2, 2018
First decision: August 9, 2018
Revised: September 14, 2018
Accepted: November 2, 2018
Article in press: November 2, 2018
Published online: November 12, 2018
Processing time: 136 Days and 15.6 Hours
Peer-review started: July 2, 2018
First decision: August 9, 2018
Revised: September 14, 2018
Accepted: November 2, 2018
Article in press: November 2, 2018
Published online: November 12, 2018
Processing time: 136 Days and 15.6 Hours
Core Tip
Core tip: miRNAs have been recently identified as a mechanism for regulating protein content in several cell types including platelets. In fact, certain miRNAs have been recently associated with some platelet-related pathologies. Moreover, changes in the miRNAs expression profiles have been evidenced in platelet activated by certain agonists. So, future researches will be needed to provide more information regarding platelet miRNAs in order to be used as an alternative therapy to the nowadays antiplatelet drugs.